SME Pharma Log on to Off-Patent Mart (India)
This article was originally published in PharmAsia News
In the next few years, a number of small to medium size Indian pharmaceutical manufacturers will be jumping on the high-quality manufacturing bandwagon. Joining such giants as Ranbaxy and Dr Reddy's, companies setting up these facilities have their sights set on penetrating the stiffly regulated U.S. and European drug markets. In the next few years, a number of blockbuster drugs will be going off-patent, paving the way for Indian generics producers to swoop into the market. Currently, there are between 40 and 50 new facilities expected to be commissioned in the next year or so. These new plants will join more than 100 plants already certified by the U.S. FDA. Already 20 percent to 30 percent of active pharmaceutical ingredients for U.S. drugs are produced in India. That figure is expected to grow by 10 percent to 15 percent in the next several years. Companies with new facilities in the works include Bal Pharma, Paras Pharma, Venus Remedies, Syrya Organics and Chemicals, UnijulesLife Sciences, Centaur Pharma, Flamingo Pharma, Kemwell, Coral Labs, Ipca Labs, Poly Medicure, Twilight Likaka, RPG Life Sciences, Ankur Drugs, and Alpa Labs. (Click here for more
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.